Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 12/20 | 0.41 |
| ▸ | FNTA | P49354 | 5/20 | 0.39 |
| ▸ | FNTB | P49356 | 5/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30536718 | 0.91 | ENPEP (0.39) | ENPEP | |
| SCHEMBL29476521 | 0.91 | FNTA (0.47) | FNTAFNTBACE | |
| SCHEMBL29641501 | 0.90 | CTSD (0.44) | ENPEP | |
| SCHEMBL29559148 | 0.90 | FNTA (0.40) | FNTAFNTBMMEACE | |
| SCHEMBL31318666 | 0.89 | ENPEP (0.41) | ENPEPMMEACECPA1ACE2 | |
| SCHEMBL29511087 | 0.89 | FNTA (0.38) | FNTAFNTBMMEACE | |
| SCHEMBL1984006 | 0.88 | FNTA (0.39) | FNTAFNTBMMEACE | |
| SCHEMBL1984002 | 0.88 | FNTA (0.39) | FNTAFNTBMMEACE | |
| SCHEMBL30684916 | 0.88 | LNPEP (0.42) | ENPEPMMEACECPA1ACE2 | |
| SCHEMBL20397486 | 0.87 | ANPEP (0.40) | ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12285460-B2 | Pharmaceutical compositions | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | ENPEP 440/4885FNTA 716/4885FNTB 2340/4885 |
| US-12285460-B2 | Pharmaceutical compositions | PCTP, SLC27A1, CETP | ENPEP 440/4885FNTA 716/4885FNTB 2340/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | ENPEP 323/4885FNTA 3268/4885FNTB 3846/4885 |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | ARGLU1, FFAR3, ASNS | ENPEP 178/4885FNTA 1357/4885FNTB 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.